胆固醇代谢与非酒精性脂肪性肝炎的研究进展

doi:10.16352/j.issn.1001-6325.2022.07.1134

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (7): 1134-1138.doi: 10.16352/j.issn.1001-6325.2022.07.1134

胆固醇代谢与非酒精性脂肪性肝炎的研究进展

李潇潇¹, 舒祥兵², 张莉^1*

1.上海中医药大学附属龙华医院/脾胃病研究所, 上海 200032;
2.上海中医药大学附属曙光医院宝山分院老年医学科, 上海 201999

收稿日期:2021-01-22 修回日期:2021-07-02 出版日期:2022-07-05 发布日期:2022-06-29
通讯作者: * zhangli.hl@163.com
基金资助:
国家自然科学基金青年科学基金(81804020)

Progress on cholesterol metabolism and non-alcoholic steatohepatitis

LI Xiao-xiao¹, SHU Xiang-bing², ZHANG Li^1*

1. Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032;
2. Department of Geratology, Baoshan Branch of Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China

Received:2021-01-22 Revised:2021-07-02 Online:2022-07-05 Published:2022-06-29
Contact: * zhangli.hl@163.com

摘要/Abstract

摘要： 非酒精性脂肪性肝炎(NASH)是非酒精性脂肪性肝病(NAFLD)的进展形式。胆固醇是生物合成的重要物质,胆固醇代谢紊乱是NASH的重要危险因素。饮食中胆固醇在肠道中的吸收,在血液循环中的交换转运以及在细胞中合成与代谢均可影响肝脏脂质代谢。胆固醇累积诱导的巨噬细胞活化与多种细胞器功能障碍、炎性细胞因子的分泌密切相关。此外,胆固醇-胆汁酸代谢亦可影响NASH形成和进展过程。

关键词: 胆固醇, 非酒精性脂肪性肝炎, 巨噬细胞, 炎性反应, 胆汁酸

Abstract: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD). Cholesterol is an essential substance for biological process. Intestinal absorption of dietary cholesterol, as well as circulating lipoprotein exchange, intracellular cholesterol synthesis and metabolism influence hepatic lipid metabolism. It is indicated that the dysfunction of organelles and the secretion of inflammatory cytokines contributed to the activation of cholesterol-loaded macrophage. Besides, cholesterol and bile acid metabolism can also trigger to the development and progression of NASH.

Key words: cholesterol, non-alcoholic steatohepatitis, macrophage, inflammation, bile acid

中图分类号:

R589

李潇潇, 舒祥兵, 张莉. 胆固醇代谢与非酒精性脂肪性肝炎的研究进展[J]. 基础医学与临床, 2022, 42(7): 1134-1138.

LI Xiao-xiao, SHU Xiang-bing, ZHANG Li. Progress on cholesterol metabolism and non-alcoholic steatohepatitis[J]. Basic & Clinical Medicine, 2022, 42(7): 1134-1138.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2022.07.1134

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2022/V42/I7/1134

参考文献 21

[1]	Nihei W, Nagafuku M, Hayamizu H, et al. NPC1L1-dependent intestinal cholesterol absorption requires ganglio-side GM3 in membrane microdomains[J]. J Lipid Res, 2018, 59: 2181-2187.
[2]	Zuo H, Su X, Jin Y, et al. Transthyretin regulated by linc00657/miR-205-5p promoted cholesterol metabolism by inducing SREBP2-HMGCR and inhibiting LXR alpha-CYP7A1[J]. Arch Med Res, 2020, 51: 317-326
[3]	McGettigan B, McMahan R, Orlicky D, et al. Dietary lipids differentially shape nonalcoholic steatohepatitis progression and the transcriptome of Kupffer cells and infiltrating macrophages[J]. Hepatology, 2019, 70: 67-83.
[4]	Chen HW, Yen CC, Kuo LL, et al. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells[J]. Toxicol Appl Pharmacol, 2020, 393: 114941. doi: 10.1016/j.taap.2020.114941.
[5]	Bakke SS, Aune MH, Niyonzima N, et al. Cyclodextrin reduces cholesterol crystal-induced inflammation by modulating complement activation[J]. J Immunol, 2017, 199: 2910-2920.
[6]	Ho CM, Ho SL, Jeng YM, et al. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease[J]. J Inflamm, 2019, 16: 7. doi: 10.1186/s12950-019-0211-5.
[7]	庄红, 张苏川, 刘慧地, 等. 沉默CXCL12抑制ox-LDL小鼠巨噬细胞系RAW264.7泡沫化和凋亡[J]. 基础医学与临床, 2021, 41:219-224.
[8]	Ioannou GN, Van Rooyen DM, Savard C, et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH[J]. J Lipid Res, 2015, 56: 277-285.
[9]	Yu Y, Liu Y, An W, et al. STING-mediated inflamma-tion in Kupffer cells contributes to progression of nonalcoholic steatohepatitis[J]. J Clin Invest, 2019, 129: 546-555.
[10]	Dang EV, McDonald JG, Russell DW, et al. Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation[J]. Cell, 2017, 171: 1057-1071.
[11]	Domínguez-Pér milton C, Mortensen R, et al. Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation[J]. J Cell Biol, 2018, 217: 3560-3576.
[13]	Guo C, Chi,Z, Jiang D, et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages[J]. Immunity, 2018, 49: 842-856.
[14]	Di Rocco M, Pisciotta L, Madeo A, et al. Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency[J]. Orphanet J Rare Dis, 2018, 13: 24. doi: 10.1186/s13023-018-0768-8.
[15]	Fiorucci S, Biagioli M, Sepe V, et al. Bile acid modu-lators for the treatment of nonalcoholic steatohepatitis (NASH)[J]. Expert Opin Investig Drugs, 2020, 29: 623-632.
[16]	Fiorucci S, Di Giorgio C, Distrutti E. Obeticholic acid: an update of its pharmacological activities in liver dis-orders[J]. Handb Exp Pharmacol, 2019, 256: 283-295.
[17]	Briand F, Brousseau E, Quinsat M, et al. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the diet-induced NASH (DIN) hamster model[J]. Eur J Pharmacol, 2018, 818: 449-456.
[18]	Carino A, Marchianò S, Biagioli M, et al. Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis[J]. Faseb J, 2019, 33: 2809-2822.
[19]	Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites[J]. Gut, 2021, 70: 761-774.
[20]	Beaumont M, Neyrinck AM, Olivares M, et al. The gut microbiota metabolite indole alleviates liver inflammation in mice[J]. Faseb j, 2018, 32: fj201800544. doi: 10.1096/fj.201800544.
[21]	Canyelles M, Tondo M, Cedó L, et al. Trimethylamine N-oxide: a link among diet, gut microbiota, gene regulation of liver and intestine cholesterol homeostasis and HDL function[J]. Int J Mol Sci, 2018, 19: 3228. doi: 10.3390/ijms19103228.

[1]	王珊, 杨华昱, 孙颖, 马清. 老年血液透析患者血清miR-21与T细胞相关[J]. 基础医学与临床, 2022, 42(8): 1188-1193.
[2]	王远卓, 郑清月, 张翰林, 仇文颖, 王涛, 马超. 小胶质细胞在阿尔茨海默病神经炎性反应中作用的研究进展[J]. 基础医学与临床, 2022, 42(8): 1310-1313.
[3]	姜秀芳, 耿亚楠, 阳盛洪, 魏平, 赵名, 朱玲玲. 绞股蓝皂苷减轻脂多糖诱导大鼠肾上腺嗜铬细胞瘤细胞系PC12损伤[J]. 基础医学与临床, 2022, 42(6): 908-912.
[4]	马瑞, 杨黎星, 陈秋霞, 仇佳星, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐对小鼠胶质瘤相关巨噬细胞系促癌表型的影响[J]. 基础医学与临床, 2022, 42(5): 701-707.
[5]	康锦钰, 罗佳, 高泽天, 郑文涛, 刘爱明, 宋毓飞. 胆汁淤积性肝损伤炎性反应机制的研究进展[J]. 基础医学与临床, 2022, 42(5): 809-813.
[6]	李蓉, 朱含月. 酮咯酸氨丁三醇抑制膝骨关节炎模型大鼠炎性反应[J]. 基础医学与临床, 2022, 42(3): 417-422.
[7]	王会娟, 王继红, 赵兴山, 刘巍. 匹伐他汀对合并脂代谢异常的稳定型冠心病患者HDL-C水平及功能的影响[J]. 基础医学与临床, 2022, 42(3): 467-471.
[8]	张爽, 李之凡, 钱杰, 吴娜琼. 腔内影像学方法评价降脂治疗对冠状动脉粥样硬化斑块影响的研究进展[J]. 基础医学与临床, 2022, 42(3): 366-371.
[9]	张琦悦, 张伟丽. 血管老化在动脉粥样硬化中的研究进展[J]. 基础医学与临床, 2022, 42(3): 372-377.
[10]	韩爽, 陈宇, 张伟丽. miR-216a对人外周血单个核细胞衍生的巨噬细胞特性的影响[J]. 基础医学与临床, 2022, 42(3): 384-388.
[11]	胡贤良, 万燕, 冯霁. 肠道菌群在妊娠期糖尿病发病中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 516-519.
[12]	郭梦然, 闵行, 叶月, 许晓双, 甄东户. 单核苷酸多态性和免疫细胞在糖尿病肾脏疾病中的研究进展[J]. 基础医学与临床, 2022, 42(2): 335-339.
[13]	邓九红, 郑超, 王声遥, 王心怡. 醋酸泼尼松对糖尿病肾病模型大鼠肾功能、肾脏炎性反应及AMPK/SIRT1信号通路的影响[J]. 基础医学与临床, 2022, 42(2): 243-248.
[14]	杨佳卉, 赵微, 解相宏, 李春美, 刘晓军, 姚红. 肝细胞特异性Sirt1缺失加重小鼠肝脏炎性反应[J]. 基础医学与临床, 2022, 42(2): 282-285.
[15]	树梦萱, 袁方晨, 周梦琪, 涂世盐, 许玥, 秦红岩. 结肠炎诱发肝脏屏障功能障碍的研究进展[J]. 基础医学与临床, 2022, 42(1): 149-153.

胆固醇代谢与非酒精性脂肪性肝炎的研究进展

Progress on cholesterol metabolism and non-alcoholic steatohepatitis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价